At a glance
| Field | Details |
|---|---|
| Brand names | Not yet approved |
| Targets | GLP-1R (single agonist, ultra-long-acting) |
| Developer | Ascletis |
| Modality | SC injection, monthly → quarterly |
| Approval status | Phase 2 complete |
| Key efficacy | Positive Phase 2 weight loss and glycemic data — [verify specific numbers] |
| Indications | Obesity, T2D |
User Sentiment
ASC30 doesn't have a broad patient community yet — Phase 2 data is limited and Western awareness is low. But the concept of quarterly dosing generates strong interest in GLP-1 communities whenever it's mentioned, particularly among people who've been on weekly therapy for a year or more and describe the injection routine as the most burdensome part of long-term treatment.
Example(What the concept means to patients)
In obesity treatment forums, when quarterly dosing comes up the reaction is consistent: "I'd stay on it forever if I only had to inject four times a year." Maintenance is the hardest part of obesity pharmacotherapy — not starting, but staying. Reducing the physical and psychological burden of indefinite weekly injections is a real clinical need the pipeline is only beginning to address.
How it works
Standard GLP-1R agonism — same mechanism as semaglutide. The innovation is entirely pharmacokinetic: a GLP-1 analog engineered with modifications that extend its half-life far beyond any currently approved drug in the class, from semaglutide's ~7 days to a target that enables monthly and eventually quarterly dosing.
The rationale: weekly injection burden is significant for a disease requiring years of maintenance therapy. A quarterly injection changes the real-world treatment experience fundamentally — four clinic or pharmacy interactions per year vs fifty-two.
Intuition(The maintenance adherence problem)
Obesity treatment is indefinite — there's no course to complete. Weekly GLP-1 injections mean ~260 injections over five years for a patient who stays on therapy. Real-world adherence data shows significant dropout over that period. A quarterly injection over the same five years is 20 injections. That's not a marginal convenience difference — it's a different behavioral and logistical burden that should produce meaningfully different real-world adherence. If ASC30 reaches equivalent efficacy at quarterly dosing, the relevant comparison isn't just the weight loss number in a Phase 3 trial; it's the weight loss maintained over years of actual use.
Trial data
Phase 2 showed positive weight loss and glycemic results consistent with GLP-1R agonism at the dose levels tested. Specific efficacy numbers not yet fully public pending publication [verify — may have been published post-2025].
What to Expect
Based on GLP-1 mechanism and ultra-long-acting design:
Month 1 — Induction dose. Drug levels build over weeks rather than peaking and troughing weekly.
Month 2–3 — Steady-state drug levels. Weight loss expected to mirror semaglutide class at comparable exposure.
Quarterly maintenance — Four injections per year. Same mechanism as weekly drugs — the difference is entirely in the pharmacokinetic engineering.
Phase 3 design and full efficacy timeline not yet public.
Dosing and administration
Monthly subcutaneous injection during induction phase, targeting quarterly maintenance dosing. Specific titration schedule not yet public [verify against any published Phase 2 protocol].
Development status
| Milestone | Status |
|---|---|
| Phase 2 | Complete — positive results |
| Phase 3 design | Pending |
| FDA filing | Timeline not yet public |
Safety profile
Phase 2 safety consistent with GLP-1 class. No novel signals identified. The ultra-long half-life raises questions about how long side effects would persist if a patient needed to stop — a tolerability consideration distinct from weekly drugs. Full profile pending Phase 3.
Who It's For
- Adults with obesity (BMI ≥ 30 or ≥ 27 with weight-related conditions)
- People who want the efficacy of GLP-1 therapy with the lowest possible injection burden
- Long-term obesity treatment patients who've described weekly injections as their biggest adherence barrier
If quarterly dosing sounds right for you, ASC30 is a Phase 2 drug — not yet available. Check in with a provider about what's currently available while the quarterly class matures.
Summary(The ASC30 picture)
Same GLP-1R mechanism as semaglutide, dramatically longer dosing interval. The clinical bet is that quarterly adherence outperforms weekly adherence over multi-year obesity treatment, making equivalent Phase 3 efficacy better real-world efficacy. Phase 3 design and enrollment timeline is the pending question.